IGC
Price
$0.30
Change
-$0.01 (-3.23%)
Updated
Jul 3 closing price
Capitalization
25.38M
33 days until earnings call
MRNA
Price
$30.49
Change
+$0.21 (+0.69%)
Updated
Jul 3 closing price
Capitalization
11.79B
25 days until earnings call
Interact to see
Advertisement

IGC vs MRNA

Header iconIGC vs MRNA Comparison
Open Charts IGC vs MRNABanner chart's image
IGC Pharma
Price$0.30
Change-$0.01 (-3.23%)
Volume$240.57K
Capitalization25.38M
Moderna
Price$30.49
Change+$0.21 (+0.69%)
Volume$6.97M
Capitalization11.79B
IGC vs MRNA Comparison Chart in %
Loading...
IGC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MRNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IGC vs. MRNA commentary
Jul 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IGC is a Hold and MRNA is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 06, 2025
Stock price -- (IGC: $0.30 vs. MRNA: $30.49)
Brand notoriety: IGC: Not notable vs. MRNA: Notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IGC: 112% vs. MRNA: 60%
Market capitalization -- IGC: $25.38M vs. MRNA: $11.79B
IGC [@Biotechnology] is valued at $25.38M. MRNA’s [@Biotechnology] market capitalization is $11.79B. The market cap for tickers in the [@Biotechnology] industry ranges from $310.37B to $0. The average market capitalization across the [@Biotechnology] industry is $2.38B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IGC’s FA Score shows that 0 FA rating(s) are green whileMRNA’s FA Score has 1 green FA rating(s).

  • IGC’s FA Score: 0 green, 5 red.
  • MRNA’s FA Score: 1 green, 4 red.
According to our system of comparison, MRNA is a better buy in the long-term than IGC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IGC’s TA Score shows that 4 TA indicator(s) are bullish while MRNA’s TA Score has 5 bullish TA indicator(s).

  • IGC’s TA Score: 4 bullish, 4 bearish.
  • MRNA’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, MRNA is a better buy in the short-term than IGC.

Price Growth

IGC (@Biotechnology) experienced а -2.42% price change this week, while MRNA (@Biotechnology) price change was +10.71% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.30%. For the same industry, the average monthly price growth was +17.40%, and the average quarterly price growth was -0.11%.

Reported Earning Dates

IGC is expected to report earnings on Aug 08, 2025.

MRNA is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+6.30% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MRNA($11.8B) has a higher market cap than IGC($25.4M). IGC YTD gains are higher at: -9.970 vs. MRNA (-26.671). IGC has higher annual earnings (EBITDA): -7.58M vs. MRNA (-3.2B). MRNA has more cash in the bank: 5.98B vs. IGC (470K). IGC has less debt than MRNA: IGC (270K) vs MRNA (745M). MRNA has higher revenues than IGC: MRNA (3.14B) vs IGC (1.24M).
IGCMRNAIGC / MRNA
Capitalization25.4M11.8B0%
EBITDA-7.58M-3.2B0%
Gain YTD-9.970-26.67137%
P/E RatioN/AN/A-
Revenue1.24M3.14B0%
Total Cash470K5.98B0%
Total Debt270K745M0%
FUNDAMENTALS RATINGS
IGC vs MRNA: Fundamental Ratings
IGC
MRNA
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
47
Fair valued
61
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9896
PRICE GROWTH RATING
1..100
6262
P/E GROWTH RATING
1..100
1002
SEASONALITY SCORE
1..100
95n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IGC's Valuation (47) in the Biotechnology industry is in the same range as MRNA (61). This means that IGC’s stock grew similarly to MRNA’s over the last 12 months.

IGC's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as MRNA (100). This means that IGC’s stock grew similarly to MRNA’s over the last 12 months.

MRNA's SMR Rating (96) in the Biotechnology industry is in the same range as IGC (98). This means that MRNA’s stock grew similarly to IGC’s over the last 12 months.

MRNA's Price Growth Rating (62) in the Biotechnology industry is in the same range as IGC (62). This means that MRNA’s stock grew similarly to IGC’s over the last 12 months.

MRNA's P/E Growth Rating (2) in the Biotechnology industry is significantly better than the same rating for IGC (100). This means that MRNA’s stock grew significantly faster than IGC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IGCMRNA
RSI
ODDS (%)
N/A
Bearish Trend 4 days ago
72%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
89%
Bearish Trend 4 days ago
81%
Momentum
ODDS (%)
Bullish Trend 4 days ago
81%
Bullish Trend 4 days ago
77%
MACD
ODDS (%)
Bearish Trend 4 days ago
90%
Bullish Trend 4 days ago
73%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
84%
Bullish Trend 4 days ago
79%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
81%
Bullish Trend 4 days ago
80%
Advances
ODDS (%)
Bullish Trend 25 days ago
83%
Bullish Trend 4 days ago
77%
Declines
ODDS (%)
Bearish Trend 7 days ago
82%
Bearish Trend 19 days ago
85%
BollingerBands
ODDS (%)
N/A
Bearish Trend 4 days ago
77%
Aroon
ODDS (%)
Bullish Trend 4 days ago
77%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
IGC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MRNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
CVRT32.350.27
+0.83%
Calamos Convertible Equity Alt ETF
BIBL42.010.27
+0.65%
Inspire 100 ETF
XBJA30.270.06
+0.20%
Innovator US Eq Acclrtd 9 Bffr ETF Jan
PBNV28.02N/A
N/A
PGIM S&P 500 Buffer 20 ETF - Nov
SPBO29.05-0.06
-0.21%
SPDR® Portfolio Corporate Bond ETF

IGC and

Correlation & Price change

A.I.dvisor tells us that IGC and KZR have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that IGC and KZR's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IGC
1D Price
Change %
IGC100%
-1.47%
KZR - IGC
31%
Poorly correlated
+2.00%
MRNA - IGC
30%
Poorly correlated
+0.69%
SMMT - IGC
30%
Poorly correlated
+8.53%
HOWL - IGC
29%
Poorly correlated
N/A
LRMR - IGC
28%
Poorly correlated
+2.89%
More

MRNA and

Correlation & Price change

A.I.dvisor indicates that over the last year, MRNA has been loosely correlated with BNTX. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if MRNA jumps, then BNTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MRNA
1D Price
Change %
MRNA100%
+0.69%
BNTX - MRNA
50%
Loosely correlated
+1.61%
ARCT - MRNA
50%
Loosely correlated
+1.17%
CRSP - MRNA
48%
Loosely correlated
+0.97%
NVAX - MRNA
45%
Loosely correlated
+0.59%
RGNX - MRNA
45%
Loosely correlated
+1.39%
More